Delcath Systems Inc.

Delcath Systems, Inc. (NASDAQ:DCTH) Releases Latest Data From Retrospective Trial Of Melphalan/HDS,

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology firm focused on the cure of primary and metastatic liver cancers, reported latest data from a retrospective trial of Melphalan/HDS. The report has been approved for oral presentation at the upcoming Regional Cancer Therapies International Symposium, to be held from February 18 – 20, 2017.

The details

The retrospective trial was performed by Moffitt Cancer Center teams in Tampa and the University of Southampton in the UK. The study assesses patient treatment results with PHP® therapy with Melphalan/HDS in subjects with primary metastatic ocular melanoma with liver metastasis cured between 2008 and 2016. The trial was directed by Dr. Alexandra Gangi.

Delcath CEO Jennifer K. Simpson, Ph.D. said that they are extremely delighted that Dr. Gangi and respective team’s research has been approved for oral presentation at this prominent event and consider that their research report will further inform on the application of Melphalan/HDS as a prospective viable additional alternative for cure of hepatic metastases in people with metastatic ocular melanoma. They look forward to reporting the details of new report after it is presented.

Delcath is an interventional oncology firm focused on advancing the therapies for primary and metastatic liver cancers. The investigational product, Melphalan Hydrochloride for application with the Delcath Hepatic Delivery System, is intended to provide high-dose chemotherapy to the liver, and at the same time controlling systemic exposure and related side effects.

The company has initiated an international Phase III FOCUS clinical study for subjects with Hepatic Dominant Ocular Melanoma and an international Phase II clinical study in the U.S. and Europe to probe the Melphalan/HDS system for the cure of primary liver cancer and intrahepatic cholangiocarcinoma. Melphalan/HDS has not been accepted by the U.S. FDA for sale in the U.S.

In the last trading session, the stock price of Delcath declined more than 24% to close the day at $0.310.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 traders350.com. All RIGHTS RESERVED.